A randomized, placebo-controlled, double-blind, ascending-dose study to determine safety, tolerability, and pharmacokinetics of vilaprisan in healthy postmenopausal Japanese women received vilaprisan as immediate-release tablets
Latest Information Update: 18 Oct 2021
At a glance
- Drugs Vilaprisan (Primary)
- Indications Endometriosis; Uterine leiomyoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 18 Oct 2021 New trial record
- 11 Oct 2021 Results published in the European Journal of Drug Metabolism and Pharmacokinetics